While Ryobi has a vast selection of power tools, most notably the Ryobi ONE+ 18V line that delivers over 300 products that ...

Prepare for winter adventures and even inclement weather with this powerful solar generator, now on sale for $90 less.

As of Nov. 5, get the Bluetti Laptop Battery Power Bank for $138.99 at Amazon, down from its usual price of $299. That's $160 ...

Select an option below to continue reading this premium story. Already a Honolulu Star-Advertiser subscriber? Log in now to continue reading. Separately, at about 11:55 a.m. Oct. 25, the owner of a ...

Techtronic Industries will invest $120 million to relocate its floor care headquarters from North Carolina to Anderson, South Carolina. The move is expected to create 120 new jobs and will consolidate ...

The leader of a labor union in Southern California who was arrested while protesting an immigration raid earlier this year will have his felony obstruction charge reduced to a misdemeanor, court ...

Scanning a loyalty card might be costing you money. Companies say they’re rewarding your devotion with points, discounts and perks. But behind the scenes, many are using these programs to monitor your ...

Oct 16 (Reuters) - A union representing more than 3,200 striking workers of Boeing said on Thursday it has filed an unfair labor practice charge against the U.S. planemaker with the National Labor ...

One item to point out is that Tvardi Therapeutics (NASDAQ:TVRD) brought its pipeline forth to public trading because of a merger it enacted with Cara Therapeutics and thus was able to list on the ...

Tivardi Therapeutics (NASDAQ:TVRD) is down ~85% in Monday trading after reporting that preliminary results from a phase 2 trial of TTI-101 in idiopathic pulmonary fibrosis showed significantly higher ...

Tvardi Therapeutics (TVRD) provided an update on preliminary data from the Phase 2 REVERT clinical trial of TTI-101 in idiopathic pulmonary fibrosis. Overall, 88 patients were randomized to TTI-101 ...

Tvardi Therapeutics shares were 30% lower, at $7.19, in premarket trading after the company said its phase 2 study for TTI-101 didn't meet its goals. TTI-101 is a small molecule therapy targeting ...